ABSTRACT: Designing drugs to treat diseases associated with articular joints, particularly those targeting chondrocytes, is challenging due to unique local environmental constraints including the avascular nature of cartilage, the absence of a closed joint compartment, and a highly cross-linked extracellular matrix. In an effort to address these challenges, we developed a novel strategy to prolong residence time of intra-articularly administered protein therapeutics. Avimer domains are naturally found in membrane polypeptides and mediate diverse protein-protein interactions. Screening of a phage Avimer domain library led to identification of several low affinity type II collagen-binding Avimers. Following several rounds of mutagenesis and reselection, these initial hits were transformed to high affinity, selective type II collagen-binding Avimers. One such Avimer (M26) persisted in rat knees for at least 1 month following intra-articular administration. Fusion of this Avimer to a candidate therapeutic payload, IL-1Ra, yielded a protein construct which simultaneously bound to type II collagen and to IL-1 receptor. In vitro, IL-1Ra_M26 bound selectively to cartilage explants and remained associated even after extensive washing. Binding appeared to occur preferentially to pericellular regions surrounding chondrocytes. An acute intra-articular IL-1-induced IL-6 challenge rat model was employed to assess in vivo pharmacodynamics. Whereas both IL-1Ra_M26 and native IL-1Ra inhibited IL-6 output when co-administered with the IL-1 challenge, only IL-1Ra_M26 inhibited when administered 1 week prior to IL-1 challenge. Collagen-binding Avimers thus represent a promising strategy for enhancing cartilage residence time of protein therapeutics. ß
Osteoarthritis (OA), the most common form of arthritis, is characterized by progressive loss of articular cartilage, development of osteophytes, pain, and loss of joint function. 1 It is estimated that symptomatic OA affects 12.1% of US adults ages 25-74, 2 and 34% of those over age 65. 3 Current first-line pharmacological options include analgesics and corticosteroids which provide short-term pain relief but prolonged use often is associated with undesirable side-effects. 4 There are no approved therapeutics that can reverse, halt, or slow disease progression. Identification of safe and effective disease-modifying OA drugs (DMOAD) represents a large unmet medical need.
Cartilage is avascular but bathed in synovial fluid present within the joint cavity. Intra-articular (IA) injection of therapeutics intended for the treatment of osteoarthritic joints is an attractive delivery option for maximizing exposure at the diseased site while reducing the risk of systemic liabilities. However, IA injections require physician assistance and carry a risk of infection, thus limiting the frequency at which they can be administered. Moreover, drug concentrations achieved post-injection rapidly dissipate as a result of the synovial fluid being in equilibrium with the systemic circulation. 5, 6 An additional complication exists for therapeutics that seek to target chondrocytes embedded within articular cartilage; the highly crosslinked and negatively charged extracellular matrix imposes size and charge restrictions on potential therapeutics. [7] [8] [9] Thus, the physical nature of cartilage and other unique aspects of the joint environment pose challenges for therapeutic development.
Interleukin-1 (IL-1) has emerged as a promising target for the treatment of OA. IL-1 is composed of two inflammatory cytokines, IL-1a and IL-1b, which signal by binding to the type 1 IL-1 receptor (IL-1R). 10 A related cytokine, IL-1Ra, also binds to IL-1R but functions as an antagonist of IL-1 signaling. 10 Expression of IL-1a, IL-1b, and IL-1R are up-regulated in osteoarthritic chondrocytes and cartilage, [11] [12] [13] [14] [15] [16] [17] elevated IL-1 levels are observed in synovial fluid from osteoarthritic joints, [18] [19] [20] and genetic studies have linked IL-1 family genes to OA. [21] [22] [23] [24] [25] Application of IL-1 to cartilage explants leads to metabolic changes observed in OA such as induction of metalloproteinases and aggrecanases, enhanced production of nitric oxide and prostaglandin E2, and inhibition of collagen and proteoglycan synthesis. 11, 12, 16, [26] [27] [28] [29] [30] Furthermore, addition of IL-1Ra blocks the spontaneous breakdown of collagen and proteoglycan observed in explants derived from osteoarthritic cartilage, 31 and IL-1 inhibition provides therapeutic benefit in rodent, rabbit, dog, and horse OA disease models. [32] [33] [34] [35] [36] This large body of evidence prompted several OA clinical trials of IL-1 antagonists, including recombinant IL-1Ra (Anakinra) and a monoclonal antibody targeting IL-1R. [37] [38] [39] Although to date these trials have been largely unsuccessful, the lack of efficacy may reflect failure of the protein therapeutics to provide durable target coverage rather than lack of target involvement. For example, based on evidence that chondrocytes are both producers of IL-1 as well as responders, 40 failure of tested anti-IL-1R1 antibodies to provide benefit may reflect their inability to access chondrocytes within cartilage, whereas lack of success of IA-administered IL-1Ra may reflect inadequate target coverage as a result of its rapid clearance from the joint.
Several strategies are being investigated for maintaining IA-injected therapeutics within the joint space, including encapsulation within microspheres and attachment to nanoparticles. 6, 41 Moreover, amino acid encoding sequences have been described which act as tethers to facilitate binding of proteins to cartilage and synovial tissues. [42] [43] [44] We now describe a joint-retention strategy based on identification of novel Avimer TM scaffolds. Avimers are derived from naturally occurring A-domains of human cell surface proteins; these small (<40 amino acid) domains mediate a vast array of protein-protein interactions. 45 High affinity Avimers that bind specifically to type II collagen (CIIbinding Avimers) were identified by library screening and optimization. Fluorescently tagged CII-binding Avimers associated with cartilage ex vivo and persisted in a rat joint following IA injection. Fusion of a high affinity CII-binding Avimer (M26) to the C-terminus of IL-1Ra yielded a construct capable of binding simultaneously to type II collagen and soluble IL-1R. Compared with native IL-1Ra, IL-1Ra_M26 provided a prolonged pharmacodynamic response following IA administration to rats. Thus, Avimer-based CII-binding domains provide a novel approach for engineering protein therapeutics capable of providing a durable cartilage-centric response.
MATERIALS AND METHODS

Generation of Type II Collagen-Binding Avimers
Avimer libraries were constructed in the fUSE5 M13 phage vector (provided by George Smith, University of Missouri) and screened against immobilized protein targets as previously described. 45 A detailed description of the screening and mutagenesis strategy employed in the selection of CIIbinding Avimers is provided in the supplemental section. Selected phage-derived Avimers were cloned into a pEVE expression plasmid, transformed into BL21(DE3) Gold cells (Stratagene, San Diego, CA), and purified as previously described. 45 The complete amino acid sequence of an example CII-binding Avimer construct (M26) is shown in Supplemental Figure S1 .
Generation of IL-1Ra/Avimer Fusion Proteins
Avimer M26 and human IL-1Ra were linked as fusion proteins via a GGGGSGGGGS ((G4S)2) linker with IL-1Ra positioned either at the N-or C-terminus. A negative control (NC) fusion protein was constructed by fusing an irrelevant Avimer (M07) to human IL-1Ra in the same manner. To facilitate purification, fusion proteins were engineered to contain an N-terminal 6-His tag. The complete amino acid sequence of the IL-1Ra_M26 fusion construct is shown in Supplemental Figure S1 . For imaging studies Avimers or fusion proteins were labeled with biotin, FITC, AF647, or AF680 using Pierce conjugation kits and recommended protocols.
HuIL-1Ra_M26 Avimer Dual Binding ELISA All assay incubations were carried out at RT with shaking. Ninety-six-well Maxisorp ELISA plates were coated with human type II collagen (20 nM in 20 mM Tris, pH 7.5, 150 mM NaCl; Chondrex, Redmond, WA). After a 1.5-h incubation, binding solutions were decanted and the wells treated with blocking buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM CaCl 2 , 1% BSA). Dose-response curves (starting at 1 mM) were generated by serially diluting huIL-1Ra_M26 fusion, M26 alone, or huIL-1Ra in assay buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM CaCl 2 , 0.1% BSA, and 0.05% Tween-20). Diluted proteins were added to CII-coated wells, the plates were incubated for 1.5 h, and then washed three times with wash buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM CaCl 2 and 0.05% Tween-20). HuIL-1RI-Fc fusion protein (20 nM; Amgen) in assay buffer was added to each well of the washed plates and incubated for 1 h. After washing three times, anti-huIgG-HRP (0.67 nM; BioSource International, Camarillo, CA) was added to each well, plates were incubated for 1 h, and then washed three times prior to addition of HRP substrate mix (TMB/H 2 O 2 ; reaction stopped with 2N H 2 SO 4 ). Plates were read at OD 450 nm using SpectraMax Plus.
Source of Human Cartilage Explants
Non-diseased human cartilage explants were purchased from Articular Engineering (Northbrook, IL). Information obtained from the provider states: "Human cartilage tissue is aseptically dissected from all surfaces of the knee joint from cadaveric donors within 48 h of death. Full thickness cartilage slices are selected for explant production. Each explant is created with a biopsy punch, 5 mm in diameter. All explants in a culture plate have uniform circumference. The thickness varies between 2 and 3 mm. Explants are distributed into 48-well plates (1 explant/well) in 50/50 DMEM/F12 supplemented with 10% FBS. The cultures are shipped overnight with cold packs."
In Vivo Imaging
Animal protocols and procedures were approved by the Institutional Animal Care and Use Committee of Amgen, Inc. Female Lewis rats (120-140 g; Harlan Labs, Indianapolis, IN) were housed in filter-top cages with food and water ad libitum on a 12 h light/dark cycle. Rats were anesthetized using 4% isoflurane in oxygen (1 L/min) during induction and 2% isoflurane in oxygen (0.5 L/min) delivered via nose-cone during intra-articular injection and imaging. Prior to IA injection, animals were shaved under anesthesia from the right leg to the inguinal area including the surrounding abdomen. Injection areas were cleaned after which 30 ml of fluorescently labeled material was injected through the patellar ligament and into the articular space. Animals were imaged in an IVIS Spectrum (PerkinElmer, Alkron, OH) and images were acquired using planar epi-CARTILAGE TETHERING COLLAGEN-BINDING AVIMERS illumination and Living Image software version 3.0 (PerkinElmer). For AF680 labeled probes, the excitation filter was set to 675 nm with the emission filter at 720 nm. For AF647 labeled probes, the excitation filter was set to 640 nm and the emission filter at 680 nm. All images were subjected to flatfield correction, cosmic ray correction, and read bias subtraction. Fluorescence intensity is reported in Radiant Efficiency (p/s/cm 2 /steridian) using a region of interest (ROI) positioned over the injection site of the first image acquired (Time 0) immediately after injection. The same ROI was used on all subsequent images for each individual animal to compare values across time-points. The values were graphed using GraphPad Prism version 5.0. For ex vivo imaging and comparisons to in vivo images, Radiance values are reported (p/s/cm 2 /steridian).
Ex Vivo Detection of CII-Binding Avimers in Rat Cartilage
Following IA Injection Female Lewis Rats (120-140 g) were injected IA with 30 ml of AF647-labeled Avimers as described above and euthanized 28-day post-injection. For ex vivo imaging studies, the fluorescent label was changed from AF680 to AF647 to accommodate the optimal excitation and emission configurations required by the imaging system used for the respective experiments. Duplicate samples of cartilage were dissected from both tibial plateaus and embedded in optimal cutting temperature medium (OCT). The blocks were sectioned at 4 mm on a cryostat with use of the Cryojane tape-transfer system. Sections were mounted onto 4X-adhesive slides and "flashed" 2X with UV light to promote adherence of the tissues to the slides. Slides were air dried, and hydrated with PBS, 0.05% Tween. Blocking was performed for endogenous proteins, avidin, biotin, and endogenous peroxidase. Sections were washed in-between each blocking step. Samples were reviewed using the 647 nM wavelength on a Nikon fluorescent microscope controlled by NIS Elements software. Each test sample was reviewed using the "autoexposure" feature of the software to determine the optimal exposure time for that sample. Negative control samples were subsequently reviewed, and the exposure time adjusted so that background fluorescence was just barely visible (3 s). Subsequently, photomicrographs of one representative animal from each group were collected using the optimal exposure time of the brightest sample (500 ms).
Multiphoton Imaging
Human non-diseased cartilage explants (5 mm in diameter) were obtained from Articular Engineering and maintained in a 50/50 mixture of DMEM/F12 media supplemented with 10% FBS (1 explant/well; 48-well plates). The serum concentration was lowered to 1% for 24 h prior to the start of each study. To assess binding and penetration of CII-binding Avimers, human cartilage explants were incubated with 2.5 mM FITC-labeled Avimers for 5 days at 37˚C in low serum media. At the end of this culture period, explants were placed in 35 mm glass-bottom dishes (MatTek Corporation, Ashland, MA) and Z-stack imaging was performed using a Zeiss LSM 510 META NLO imaging system equipped with a Coherent Chameleon Ti-sapphire tunable multiphoton laser; an 800 nm laser line was used as excitation wavelength and appropriate band-pass filters were used as emission filters for second harmonic generation (SHG) and FITC signals.
Three-dimensional projection movies were generated using Imaris software (Bitplane).
To demonstrate binding of the IL-1Ra_M26 fusion construct to human cartilage, explants were incubated with 2.5 mM of an AF647-labeled construct. Similar concentrations of AF647-labeled M26, AF647-labeled M07 (negative control Avimer), and AF647-labeled IL-1Ra were incubated with separate explants. These cultures were incubated 24 h at 37˚C in low serum media followed by extensive washing with PBS. Explants then were incubated with fresh media at 37˚C for an additional 3 days. At Day 0 or Day 3 postconstruct incubation, explants were placed in a 35 mm glassbottom dishes and three-dimensional image acquisition and data acquisition/processing conducted as above.
In Vitro Binding of CII Avimers to Human Cartilage
OCT-embedded human cartilage was sectioned at 4 mm on a cryostat with use of the Cryojane tape-transfer system. Sections were mounted and blocked as described above. Biotinylated Avimers (M26 and M07) were added to mounted sections at 10 mg/ml (in PBS, 0.05% Tween) and incubated overnight at 4˚C. Slides were washed, incubated with Streptavidin-AF647 for 30 min at RT, then washed and placed under a coverslip using Prolong Gold Mounting Medium containing DAPI nuclear stain (Invitrogen, Waltham, MA). Images were acquired using NIS elements v3.0 software at 647 nM on a Nikon Eclipse 50i fluorescent microscope illuminated by an EXFO Excite 120 light source. Positive and negative control images were collected using identical exposure times.
IA Rat IL-1b Challenge Model
Male Sprague-Dawley rats (250-275 g; Harlan Labs) were housed in filter-top cages with food and water ad libitum on a 12-h light/dark cycle. All studies employed N ¼ 6/cohort. For IA injections, rats were anesthetized with 1.5-4% isoflurane þ O 2 and maintained under a nose cone for the duration of the procedure. The area over the patella was shaved, disinfected, and 30 ng of rat IL-1b in 50 ml of PBS was injected into the knee joint using a 28 gauge needle. Rats injected with 50 ml of PBS served as vehicle controls. At 4 h post-IL-1b injection, knee joints were lavaged with 100 ml saline and the lavage fluids digested with hyaluronidase (500 U/ml; Sigma-Aldrich, St. Louis, MO). IL-6 levels within lavage fluids were determined by ELISA (R&D Systems, Minneapolis, MN).
RESULTS
Generation of Type II Collagen-Binding Avimer Domains
To generate CII-binding Avimers, libraries constructed in the fUSE5 M13 phage vector were panned and screened against purified human and rat type II collagen. After three rounds of panning, three monomers (M02, M03, and M05) were identified that displayed weak binding to human and rat type II collagen and no detectable binding to human cartilage. An initial round of affinity maturation yielded Avimers with sub-nM affinities for type II collagens, and detectable binding to pulverized human cartilage ( Fig. 1 ). The M18 and M26 Avimers bound specifically to type II collagen and did not bind to closely related type VI and type IX collagen family members or to human aggrecan (Fig. 2) . The M18 and M26 Avimers bound to rat type I collagen, but binding was 780-fold weaker than that observed with rat type II collagen; M26 and M18 displayed negligible binding to human type I collagen (Fig. 2) .
To characterize the binding properties of CII-binding Avimers toward human cartilage in vitro, M26 and a negative control Avimer, M07, were biotinylated and incubated with human cartilage sections. M26 bound within the superficial zone of human cartilage yielding a diffuse and pericellular staining pattern (Fig. 3A) ; no significant binding of the negative control Avimer M07 was observed (Fig. 3A) . Following incubation of FITClabeled M26 and FITC-labeled M07 with intact human cartilage explants, a dramatic difference in accumulation of the labeled Avimers was observed (Fig. 3B) . Representative multiphoton-induced second harmonic generation (SHG) images originating from fibrillar collagen are depicted in blue while the FITC-labeled Avimers are shown in green (Fig. 3B) . The SHG images are consistent with superficial zone cartilage and show an abundance of intact type II collagen fibrils present in the culture explants. Specific diffuse and pericellular accumulation of the M26 Avimer, but not the M07 Avimer, is observed around lacunae where chondrocytes reside (Fig. 3B) . As indicated by overlap of the SHG and fluorescent images, location of the M26 Avimer coincides with type II collagen fibrils. Three-dimensional projection movies were generated to better highlight cartilage penetration observed up to 30 microns below the explant surface with the M26 Avimer (Supplemental Movie S1). To quantify the FITC signal for the two Avimers, mean fluorescence intensity was measured from Z-stack images. Quantification of the mean fluorescence intensity (Fig. 3C) confirms accumulation of the M26 Avimer relative to M07.
AF680-Labeled CII-Binding Avimers Persist in the Rat Knee
Joint Following IA Administration AF680-labeled Avimers were injected into rat knee joints and imaged longitudinally over the course of 28 days. AF680-labeled M26 signals persisted at levels well above baseline values throughout the 28-day observation period (Fig. 4) . The highest intensity signal was observed immediately post-injection after which the signal declined over the ensuing 72 h before reaching a long-lived relatively steady value well above baseline (Fig. 4A) . In contrast, the majority of AF680-labeled negative control (NC) Avimer M07 was cleared from the joint within 24 h, and no signal was detected beyond 144 h (Fig. 4A) . Ex vivo imaging of dissected tibia and femur revealed that the fluorescence signal from AF680-labeled M18, an Avimer with a similar affinity as M26, was located on both surfaces 1-day post-injection ( Fig. 4B) . In contrast, little signal was associated with tibia and femurs dissected from animals injected with AF680-labeled NC Avimer. Confocal imaging of articular cartilage isolated from rat knee joints 28 days following a single IA injection of AF647-labeled M26 
CARTILAGE TETHERING COLLAGEN-BINDING AVIMERS
confirmed the presence of the labeled CII-binding Avimer and provided evidence of residence below the articular cartilage surface (Fig. 4C) . In contrast, no fluorescence was detected in cartilage sections recovered from animals injected with an AF647-labeled NC Avimer (Fig. 4C) . Taken together, these data demonstrate that type II collagen-binding Avimer domains are capable of binding specifically to articular cartilage matrixes both in vitro and in vivo.
Generation and Characterization of IL-1Ra/CII-Binding Avimer Fusions
To demonstrate that CII-binding Avimers can prolong joint residence time of a protein therapeutic payload, IL-1Ra was selected as a proof of concept molecule. To this end, M18 and M26 CII Avimers were fused to IL-1Ra in two orientations, at the N-or C-terminus. Fusion of a CII-binding Avimer to IL-1Ra in either orientation had minimal impact on binding to soluble IL-1R1 (Figs. 5A and S2A) . However, fusion of IL-1Ra to the C-termini of CII-binding Avimers greatly diminished binding to human type II collagen (Fig. 5B) . In contrast, fusion of IL-1Ra to the N-terminus of the CII-binding Avimers produced fusions that retained their ability to bind CII (Fig. 5B ). Relative to M26 alone, the IL-1Ra_M26 construct showed a modest sevenfold reduction in binding affinity for type II collagen when assessed in an AlphaScreen competition assay (Fig. S2B) . A dual ELISA-binding format was employed to demonstrate that the IL-1Ra_M26 fusion binds IL-1R and CII simultaneously. Plates pre-coated with type II collagen were incubated with IL-Ra constructs and then exposed to biotinylated soluble IL-1R1. When IL1Ra_M26 was employed, a high amount of biotinylated receptor was captured on the plate (Fig. 5C ). In contrast, when IL1-Ra_M07 or native IL-1Ra were employed, little biotinylated receptor was captured (Fig 5C) . Similar results were obtained when the IL-1Ra fusions were first bound to pulverized human cartilage and then assessed for binding of soluble IL-1R1 (Fig. S2C ). These data demonstrate that both 1242 HULME ET AL.
domains of the IL-1Ra_M26 construct retain their respective activities. To confirm that IL-1Ra_Avimer fusions are capable of inhibiting IL-1-induced cellular responses, primary human chondrocytes were stimulated with IL-1 in the presence of increasing concentrations of the constructs and IL-8 production was assessed. Consistent with receptor binding study results (Fig. 5A) , IL-1Ra fused to either the M26 or M07 Avimer was equally effective to native IL-1Ra as an inhibitor of IL-8 production (Fig. 5D) . Moreover, when human cartilage explants were stimulated with IL-1b, IL-1Ra_M26 was as effective as native IL-1Ra or IL-1Ra fused to an irrelevant Avimer at blocking IL-8 production indicating that the presence of M26 does not impede the receptor antagonist from entering cartilage and competing with IL-1 for binding to chondrocyte receptors (Supplemental Fig. S3) . Finally, to demonstrate that the IL1Ra_M26 construct can bind to cartilage, explants derived from superficial zone cartilage were incubated with AF647-labeled constructs and subsequently imaged. Similar to the single domain M26 Avimer, the IL-1Ra_M26 fusion construct showed a pronounced accumulation within cartilage (Fig. 5E ).
In contrast, the IL-1Ra_M07 construct showed no significant accumulation (Fig. 5E) . Importantly, when construct-loaded cartilage explants subsequently were incubated for an additional 72 h, both the M26 and IL-1Ra_M26 constructs remained bound (Fig. 5F ). As observed earlier, it is interesting to note that the strongest accumulation is observed in regions of the lacunae where chondrocytes reside.
IA Rat IL-1b Challenge Model
An in vivo pharmacodynamic model was developed to compare activity of IL-1Ra, with and without a CIIbinding Avimer, as antagonists of IL-1b-induced IL-6 levels in synovial fluid. Injection of IL-1b into the rat knee joint resulted in a significant increase in synovial IL-6 levels 4-h post-challenge (Fig. 6A) . Consistent with previous reports, a large molar excess of IL-1Ra was required to inhibit the IL-1b-induced response; 46,47 complete inhibition was observed using a 5,000-fold molar excess of IL-1Ra (Fig. 6A) . Simultaneous administration of IL-1Ra or IL-1Ra_M26 (5,000-fold molar excess) with the IL-1 challenge effectively suppressed IL-6 output (Fig. 6B) . On the other hand, when IL-1Ra and IL-1Ra_M26 were administered 7 days in advance of the IL-1 challenge, only IL1Ra_M26 reduced IL-6 production relative to control animals (Fig. 6B) . Thus, when fused with a CIIbinding Avimer, IL-1Ra retained biological activity in vivo and presence of the Avimer extended the duration of biological activity.
DISCUSSION
Disease modifying strategies explored for the treatment of OA have largely focused on curtailing joint CARTILAGE TETHERING COLLAGEN-BINDING AVIMERS damage or promoting repair, and have included several large molecule candidates that target chondrocytes. The avascular nature of cartilage, coupled with size restrictions on macromolecules which can enter its matrix, create special challenges for biological therapies targeting the joint space environment. 48 IA injection overcomes some of these challenges by ensuring bioavailability at the local disease site. IA injection also reduces systemic exposure, which may provide safety advantages. However, IA injection does not guarantee a durable pharmacological response as the synovial fluid is not a closed compartment. 5, 6 Hence, strategies for extending the residence time of therapeutics in the joint are being developed and include specialized formulations such as liposomes, hydrogels, micelles, microspheres and nanoparticles. 6, 41 Some formulations, such as self-assembling nanoparticles, have been shown to prolong the retention time of IL-1Ra within the joint. 49 However, most formulation strategies do not address the additional hurdle faced by biologics that target chondrocytes; viz. the need to traverse an avascular, anionic matrix that is not permeable to molecules >50 kD. [7] [8] [9] The CIIbinding Avimers described in this report may provide a means for developing durable cartilage-penetrating biological therapeutics. After just two rounds of optimization, leads from an original Avimer library screen were transformed to isoforms possessing high binding affinity and selectivity for CII. Among the optimized Avimers, M26 possessed the highest affinity for human CII (0.18 nM) and for human cartilage (1.54 nM). M26 also bound selectively to rat CII (0.05 nM affinity); cross reactivity with rat CII is not surprising given the highly conserved nature of type II collagens. In contrast, M26 demonstrated no detectable binding to human type I, VI, IX collagens or to human aggrecan. When incubated with human cartilage explants, fluorescently tagged M26 appeared to accumulate preferentially within pericellular regions surrounding chondrocytes. Whether this selective localization reflects differential localization of the CIIbinding epitope or restrictions posed by cross-linking within the matrix is unclear. Remarkably, following injection of fluorescently tagged M26 into rat knee joints, the Avimer remained detectable for up to 28-day post-injection. Ex vivo imaging of knee joints harvested from animals injected with CII-binding Avimers provided evidence that they accumulated in both tibial and femoral cartilage. Moreover, confocal imaging of cartilage sections isolated from animals 28-day post-injection demonstrated that fluorescently tagged M26 Avimer remained within cartilage.
When fused to IL-1Ra, CII-binding Avimers did not impact IL-1Ra's activity as an antagonist of IL-1. However, the ability of CII-binding Avimers to bind to collagen was affected by their positioning. When appended to the N-terminus of IL-1Ra, both M26 and M18 showed weak binding to CII. However, when attached at the C-terminus of IL-1Ra, both Avimers demonstrated high binding affinities to human CII. Importantly, the IL-1Ra_M26 construct binds both CII and IL-1R simultaneously, indicating that the two binding domains function independently of the other's occupancy state. Like the M26 Avimer itself, fluorescently tagged IL-1Ra_M26 bound selectively to human cartilage explants with the highest accumulation occurring in pericellular locations.
As a proof-of-concept that CII-binding Avimers can extend the therapeutic utility of IL-1Ra, native human IL-1Ra and IL-1Ra_M26 were compared as antagonists of an in vivo IL-1b response. Following IA injection of IL-1b into rat knee joints, levels of synovial fluid IL-6 increased. As expected, co-injection of native IL-1Ra suppressed the IL-6 response, provided the antagonist was present at a 5,000-fold excess over the cytokine, consistent with previous studies. 46, 47 Likewise, IL-1Ra_M26 co-injected with IL-1b inhibited IL-6 production. However, when injected 1 week prior to the IL-1b challenge, only IL-1Ra_M26-treated animals showed evidence of a pharmacological response. Therefore, the IL-1Ra_M26 conjugate may represent a novel therapeutic modality for the treatment of OA.
CII-binding Avimers provide a mechanism for tethering therapeutic payloads to cartilage and for prolonging residence time within joints. We are mindful that there will be significant size and/or charge limitations to the types of payloads that can be successfully appended to the CII-binding Avimers, and that additional studies are needed to establish that the Avimer constructs can effectively penetrate fullthickness human cartilage. Nevertheless, CII-binding Avimers represent a versatile option for extending pharmacodynamic durability of protein therapeutics targeting articular cartilage. With the ultimate goal of developing a novel DMOAD candidate, results presented here provide motivation for further optimization of an IL-1Ra_CII-binding Avimer construct and preclinical evaluation.
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